Searched for
INVAGEN
Cipla unit recalls one lot of medication in US due to seal integrity issueDrug major Cipla's subsidiary is voluntarily recalling one lot of medication in the US due to seal integrity issues. InvaGen Pharmaceutical...- Stocks in news: SJVN, Cipla, Infosys, Zydus, Apollo TyresCipla's subsidiary InvaGen's manufacturing plant has received five inspectional observations in Form 483 from USFDA.
- Cipla unit gets notice from US firm for termination of acquisition deal"Since the second stage closing could not be completed as per the agreed timelines, in the terms of the SPMA, InvaGen has received a notice...
- Cipla Q3 profit declines 17% to Rs 333 crore, misses estimatesET NOW analysts had anticipated a profit of Rs 400 crore for the December quarter.
- Cipla's subsidiary to acquire US-based Avenue Therapeutics for $ 215 millionAt the second stage, InvaGen or its affiliates will acquire the remaining shares of Avenue's common stock, for up to USD 180 million in the...
- Cipla gets USFDA nod for generic version of Renvela tabletsThe approved product is a generic equivalent to the reference listed drug (RLD), Renvela tablets, 800 mg of Genzyme Corporation, said Cipla.
- Cipla at the bottom end of margin in industry: Umang Vohra, MD & Global CEOFor the leverage to be more in the future, we need to have more unlocking in the US pipeline, which is what most analysts are also saying.
- Cipla gets USFDA nod for generic anti-depressant drugThe company's tablets are generic versions of Valeant's Wellbutrin XL tablets in the same strengths, Cipla said.
- Cipla should launch 10 odd products in the FY17: Umang Vohra, Global COO"Cipla FY16 guidance of 20-22 per cent revenue growth and 100 to 150 bps margin improvement for this year does not include InvaGen"
- Cipla seals Invagen and Exelan deals in USThe deal closure, that involved approvals from the US regulatory agencies, will see Cipla vault its sales from that market to around $400 m...
- PuraCap suit may impact Cipla's $550-million dealIn an email response seeking comment, PuraCap said its complaint was publicly available at the US District Court for the Southern District ...
- Twelve stocks in focus in Wednesday's tradeIndian markets are expected to trade in a range. Here is a list of twelve stocks which are likely to remain in focus today.
- Analysts bet on Cipla as acquisitions expected to boost company's growthAcquisitions of two companies in the US will help Cipla increase its foothold in the market and has made analysts bullish on the counter.
- Goal to make US contribute 20% to our business by 2020: Sudhanshu Priyadarshi, CiplaWe have had a good beginning in the US since our ‘go live’ in January 2015 and we expect to continue our growth trajectory there.
- Cipla's ratings unlikely to be impacted by US acquisitions: India RatingsIndia Ratings & Research today said Cipla's ratings are unlikely to be affected by the recent cash-rich acquisitions of two US-based compan...
- Nomura neutral on Cipla, target Rs 689Cipla has acquired a portfolio of largely plain vanilla oral solids where its capabilities are already well-established, and hence the acqu...
- Post Invagen sale, Hetero says to strengthen US operationsCipla said the group, through its subsidiary Camber Pharmaceuticals Inc., will continue to strengthen its operations in the US.
- InvaGen, Exelan acquisition will give Cipla manufacturing plant, R&D base in USCipla on Friday fulfilled a longstanding desire to expand its beachhead in the US by buying Hetero Pharma’s US business for about $550 mill...
- Cipla surges on US acquisitions worth $550 millionCipla shares climbed over 3% in morning trade after the company said its UK-based subsidiary, Cipla EU, will acquire two US-based companies.
- US FDA approves Glenmark's Nabumetone & Hydroxyzine HydrochlorideGlenmark Pharmaceuticals Inc, US a subsidiary of Glenmark Pharmaceuticals has initiated the marketing and distribution of Nabumetone tablet...
Load More
